Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.
Treatment with the antimalarial drug hydroxychloroquine (HCQ) has been associated with reduced risk of thrombosis in the antiphospholipid (aPL) syndrome (APS) and, in an animal model of APS, with reduction of experimentally induced thrombosis. Recognition of beta2-glycoprotein I (beta2GPI) by aPL antibodies appears to play a major role in the disease process. We therefore used the techniques of ellipsometry and atomic force microscopy (AFM) to investigate whether HCQ directly affects the formation of aPL IgG-beta2GPI complexes on phospholipid bilayers. HCQ, at concentrations of 1 mug/mL and greater, significantly reduced the binding of aPL-beta2GPI complexes to phospholipid surfaces and THP-1 (human acute monocytic leukemia cell line) monocytes. The drug also reduced the binding of the individual proteins to bilayers. This HCQ-mediated reduction of binding was completely reversed when the HCQ-protein solutions were dialyzed against buffer. HCQ also caused modest, but statistically significant, reductions of clinical antiphospholipid assays. In conclusion, HCQ reduces the formation of aPL-beta2GPI complexes to phospholipid bilayers and cells. This effect appears to be due to reversible interactions between HCQ and the proteins and may contribute to the observed reduction of thrombosis in human and experimental APS. These results support the possibility that HCQ, or analogous molecules, may offer novel nonanticoagulant therapeutic strategies for treating APS.
Rand
Jacob H
JH
Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. jrand@montefiore.org
Wu
Xiao-Xuan
XX
Quinn
Anthony S
AS
Chen
Pojen P
PP
Hathcock
James J
JJ
Taatjes
Douglas J
DJ
D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000737:chemistry / Q000378:metabolism*; D000925:Anticoagulants / Q000494:pharmacology; D000936:Antigen-Antibody Complex / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D000962:Antimalarials / Q000494:pharmacology; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000188:drug therapy; D002460:Cell Line; D006801:Humans; D006886:Hydroxychloroquine / Q000494:pharmacology*; D066298:In Vitro Techniques; D008051:Lipid Bilayers / Q000378:metabolism; D018625:Microscopy, Atomic Force; D046912:Multiprotein Complexes / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D053482:beta 2-Glycoprotein I / Q000737:chemistry / Q000378:metabolism*
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D000936:Antigen-Antibody Complex; D000962:Antimalarials; D008051:Lipid Bilayers; D046912:Multiprotein Complexes; D010743:Phospholipids; D053482:beta 2-Glycoprotein I; D006886:Hydroxychloroquine